A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
Completed · Phase 1
Conditions studied: Neoplasms
In brief
To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Key facts
- Study ID
- NCT02222922
- Run by
- Pfizer
- People needed
- 138
- Starts
- 2014-10-17
- Expected to finish
- 2019-11-05
- Last updated by the study team
- 2020-12-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama at Birmingham — Birmingham, Alabama, United States
- University of Alabama at Birmingham — Birmingham, Alabama, United States
- Scottsdale Healthcare Hospitals DBA HonorHealth — Scottsdale, Arizona, United States
- University of California Davis Comprehensive Cancer Center — Sacramento, California, United States
- University of California Davis Medical Center — Sacramento, California, United States
- Stanford Cancer Center — Stanford, California, United States
- Stanford Hospital and Clinics — Stanford, California, United States
- University of Chicago Medicine — Chicago, Illinois, United States
- START Midwest — Grand Rapids, Michigan, United States
- South Texas Accelerated Research Therapeutics, LLC — San Antonio, Texas, United States
- Inova Fairfax Hospital Woodburn GYN Infusion Center — Annandale, Virginia, United States
- Mid Atlantic Gynecologic Oncology and Pelvic Surgery Associates (MAGOPSA) — Annandale, Virginia, United States
- Fairfax Radiological Consultants — Fairfax, Virginia, United States
- Inova Schar Cancer Institute — Fairfax, Virginia, United States
- Inova Loudon Hospital — Leesburg, Virginia, United States
- Hospital Universitario Fundacion Jimenez Diaz — Madrid, Spain
- Hospital Universitario Madrid Sanchinarro — Madrid, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.